nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP17A1—ovarian follicle—ovarian cancer	0.0947	0.631	CbGeAlD
Metoclopramide—Sunitinib—CHEK2—ovarian cancer	0.0147	0.891	CrCbGaD
Metoclopramide—CYP17A1—gonad—ovarian cancer	0.00869	0.0579	CbGeAlD
Metoclopramide—CYP17A1—female reproductive system—ovarian cancer	0.00776	0.0517	CbGeAlD
Metoclopramide—CYP11B2—lymph node—ovarian cancer	0.00743	0.0495	CbGeAlD
Metoclopramide—CYP17A1—female gonad—ovarian cancer	0.00706	0.047	CbGeAlD
Metoclopramide—CYP17A1—testis—ovarian cancer	0.00626	0.0417	CbGeAlD
Metoclopramide—Bronchospasm—Melphalan—ovarian cancer	0.00557	0.00721	CcSEcCtD
Metoclopramide—Atrioventricular block—Paclitaxel—ovarian cancer	0.00547	0.00708	CcSEcCtD
Metoclopramide—Neutropenia—Topotecan—ovarian cancer	0.00541	0.007	CcSEcCtD
Metoclopramide—Respiratory failure—Paclitaxel—ovarian cancer	0.0054	0.00699	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Paclitaxel—ovarian cancer	0.0053	0.00687	CcSEcCtD
Metoclopramide—Neutropenia—Melphalan—ovarian cancer	0.00529	0.00686	CcSEcCtD
Metoclopramide—Hallucination—Chlorambucil—ovarian cancer	0.00517	0.0067	CcSEcCtD
Metoclopramide—Wheezing—Paclitaxel—ovarian cancer	0.00515	0.00667	CcSEcCtD
Metoclopramide—Urinary incontinence—Paclitaxel—ovarian cancer	0.00512	0.00663	CcSEcCtD
Metoclopramide—Amenorrhoea—Docetaxel—ovarian cancer	0.00512	0.00662	CcSEcCtD
Metoclopramide—Fluid retention—Paclitaxel—ovarian cancer	0.00504	0.00652	CcSEcCtD
Metoclopramide—Jaundice—Melphalan—ovarian cancer	0.00492	0.00637	CcSEcCtD
Metoclopramide—Bronchospasm—Vinorelbine—ovarian cancer	0.00487	0.0063	CcSEcCtD
Metoclopramide—Rash maculo-papular—Paclitaxel—ovarian cancer	0.00482	0.00624	CcSEcCtD
Metoclopramide—CHRM1—female reproductive system—ovarian cancer	0.00463	0.0308	CbGeAlD
Metoclopramide—Neutropenia—Vinorelbine—ovarian cancer	0.00463	0.00599	CcSEcCtD
Metoclopramide—Respiratory failure—Docetaxel—ovarian cancer	0.00458	0.00593	CcSEcCtD
Metoclopramide—CYP17A1—lymph node—ovarian cancer	0.00454	0.0302	CbGeAlD
Metoclopramide—Fluid retention—Docetaxel—ovarian cancer	0.00427	0.00553	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Paclitaxel—ovarian cancer	0.00425	0.0055	CcSEcCtD
Metoclopramide—Tremor—Chlorambucil—ovarian cancer	0.00424	0.00549	CcSEcCtD
Metoclopramide—Flushing—Melphalan—ovarian cancer	0.00421	0.00545	CcSEcCtD
Metoclopramide—Agitation—Chlorambucil—ovarian cancer	0.00416	0.00539	CcSEcCtD
Metoclopramide—Angioedema—Chlorambucil—ovarian cancer	0.00414	0.00535	CcSEcCtD
Metoclopramide—Agranulocytosis—Vinorelbine—ovarian cancer	0.00412	0.00533	CcSEcCtD
Metoclopramide—Visual disturbance—Paclitaxel—ovarian cancer	0.00406	0.00526	CcSEcCtD
Metoclopramide—Atrial fibrillation—Paclitaxel—ovarian cancer	0.00406	0.00526	CcSEcCtD
Metoclopramide—Leukopenia—Chlorambucil—ovarian cancer	0.00405	0.00525	CcSEcCtD
Metoclopramide—Renal impairment—Paclitaxel—ovarian cancer	0.00405	0.00524	CcSEcCtD
Metoclopramide—Convulsion—Chlorambucil—ovarian cancer	0.00392	0.00508	CcSEcCtD
Metoclopramide—Muscle spasms—Topotecan—ovarian cancer	0.00387	0.00502	CcSEcCtD
Metoclopramide—Confusional state—Chlorambucil—ovarian cancer	0.00372	0.00482	CcSEcCtD
Metoclopramide—Angioedema—Topotecan—ovarian cancer	0.00368	0.00477	CcSEcCtD
Metoclopramide—Flushing—Vinorelbine—ovarian cancer	0.00367	0.00476	CcSEcCtD
Metoclopramide—Cardiac arrest—Paclitaxel—ovarian cancer	0.00366	0.00474	CcSEcCtD
Metoclopramide—Blood disorder—Epirubicin—ovarian cancer	0.00363	0.0047	CcSEcCtD
Metoclopramide—Leukopenia—Topotecan—ovarian cancer	0.00361	0.00467	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Docetaxel—ovarian cancer	0.0036	0.00466	CcSEcCtD
Metoclopramide—Leukopenia—Melphalan—ovarian cancer	0.00353	0.00457	CcSEcCtD
Metoclopramide—Delirium—Epirubicin—ovarian cancer	0.00353	0.00456	CcSEcCtD
Metoclopramide—Amenorrhoea—Epirubicin—ovarian cancer	0.00345	0.00447	CcSEcCtD
Metoclopramide—Atrial fibrillation—Docetaxel—ovarian cancer	0.00344	0.00446	CcSEcCtD
Metoclopramide—Visual disturbance—Docetaxel—ovarian cancer	0.00344	0.00446	CcSEcCtD
Metoclopramide—Renal impairment—Docetaxel—ovarian cancer	0.00343	0.00444	CcSEcCtD
Metoclopramide—Convulsion—Melphalan—ovarian cancer	0.00342	0.00443	CcSEcCtD
Metoclopramide—Blood disorder—Doxorubicin—ovarian cancer	0.00336	0.00435	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—ovarian cancer	0.00326	0.00422	CcSEcCtD
Metoclopramide—Dyskinesia—Epirubicin—ovarian cancer	0.00323	0.00418	CcSEcCtD
Metoclopramide—Oedema—Melphalan—ovarian cancer	0.00322	0.00417	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—ovarian cancer	0.00319	0.00413	CcSEcCtD
Metoclopramide—Fatigue—Chlorambucil—ovarian cancer	0.00318	0.00412	CcSEcCtD
Metoclopramide—Angioedema—Vinorelbine—ovarian cancer	0.00315	0.00408	CcSEcCtD
Metoclopramide—Tachycardia—Melphalan—ovarian cancer	0.00314	0.00407	CcSEcCtD
Metoclopramide—Atrioventricular block—Epirubicin—ovarian cancer	0.00313	0.00405	CcSEcCtD
Metoclopramide—Neutropenia—Paclitaxel—ovarian cancer	0.00311	0.00403	CcSEcCtD
Metoclopramide—Leukopenia—Vinorelbine—ovarian cancer	0.00309	0.00399	CcSEcCtD
Metoclopramide—Pollakiuria—Paclitaxel—ovarian cancer	0.00307	0.00398	CcSEcCtD
Metoclopramide—Palpitations—Vinorelbine—ovarian cancer	0.00305	0.00394	CcSEcCtD
Metoclopramide—Feeling abnormal—Chlorambucil—ovarian cancer	0.00304	0.00394	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Epirubicin—ovarian cancer	0.00303	0.00393	CcSEcCtD
Metoclopramide—Hypotension—Melphalan—ovarian cancer	0.00301	0.0039	CcSEcCtD
Metoclopramide—DRD2—testis—ovarian cancer	0.00301	0.02	CbGeAlD
Metoclopramide—Dyskinesia—Doxorubicin—ovarian cancer	0.00299	0.00387	CcSEcCtD
Metoclopramide—Hypertension—Vinorelbine—ovarian cancer	0.00298	0.00385	CcSEcCtD
Metoclopramide—Depression—Paclitaxel—ovarian cancer	0.00296	0.00383	CcSEcCtD
Metoclopramide—Urticaria—Chlorambucil—ovarian cancer	0.00293	0.0038	CcSEcCtD
Metoclopramide—Dyspnoea—Topotecan—ovarian cancer	0.00293	0.0038	CcSEcCtD
Metoclopramide—Body temperature increased—Chlorambucil—ovarian cancer	0.00292	0.00378	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—ovarian cancer	0.00289	0.00374	CcSEcCtD
Metoclopramide—Fluid retention—Epirubicin—ovarian cancer	0.00288	0.00373	CcSEcCtD
Metoclopramide—Dyspnoea—Melphalan—ovarian cancer	0.00287	0.00372	CcSEcCtD
Metoclopramide—Fatigue—Topotecan—ovarian cancer	0.00284	0.00367	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Doxorubicin—ovarian cancer	0.00281	0.00363	CcSEcCtD
Metoclopramide—Fatigue—Melphalan—ovarian cancer	0.00278	0.00359	CcSEcCtD
Metoclopramide—Bronchospasm—Docetaxel—ovarian cancer	0.00277	0.00359	CcSEcCtD
Metoclopramide—Rash maculo-papular—Epirubicin—ovarian cancer	0.00276	0.00357	CcSEcCtD
Metoclopramide—Tachycardia—Vinorelbine—ovarian cancer	0.00275	0.00355	CcSEcCtD
Metoclopramide—Hypersensitivity—Chlorambucil—ovarian cancer	0.00272	0.00352	CcSEcCtD
Metoclopramide—Bradycardia—Paclitaxel—ovarian cancer	0.00271	0.00351	CcSEcCtD
Metoclopramide—Feeling abnormal—Topotecan—ovarian cancer	0.00271	0.00351	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—ovarian cancer	0.00266	0.00345	CcSEcCtD
Metoclopramide—Asthenia—Chlorambucil—ovarian cancer	0.00265	0.00343	CcSEcCtD
Metoclopramide—Neutropenia—Docetaxel—ovarian cancer	0.00264	0.00341	CcSEcCtD
Metoclopramide—Hypotension—Vinorelbine—ovarian cancer	0.00263	0.0034	CcSEcCtD
Metoclopramide—Urticaria—Topotecan—ovarian cancer	0.00261	0.00338	CcSEcCtD
Metoclopramide—Body temperature increased—Topotecan—ovarian cancer	0.0026	0.00337	CcSEcCtD
Metoclopramide—Visual impairment—Paclitaxel—ovarian cancer	0.00257	0.00332	CcSEcCtD
Metoclopramide—Urticaria—Melphalan—ovarian cancer	0.00256	0.00331	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—ovarian cancer	0.00255	0.0033	CcSEcCtD
Metoclopramide—Diarrhoea—Chlorambucil—ovarian cancer	0.00253	0.00327	CcSEcCtD
Metoclopramide—Dyspnoea—Vinorelbine—ovarian cancer	0.00251	0.00325	CcSEcCtD
Metoclopramide—Flushing—Paclitaxel—ovarian cancer	0.00247	0.0032	CcSEcCtD
Metoclopramide—Jaundice—Docetaxel—ovarian cancer	0.00245	0.00317	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—ovarian cancer	0.00243	0.00314	CcSEcCtD
Metoclopramide—Fatigue—Vinorelbine—ovarian cancer	0.00243	0.00314	CcSEcCtD
Metoclopramide—Hypersensitivity—Topotecan—ovarian cancer	0.00242	0.00314	CcSEcCtD
Metoclopramide—Hypersensitivity—Melphalan—ovarian cancer	0.00237	0.00307	CcSEcCtD
Metoclopramide—Asthenia—Topotecan—ovarian cancer	0.00236	0.00305	CcSEcCtD
Metoclopramide—Agranulocytosis—Docetaxel—ovarian cancer	0.00235	0.00304	CcSEcCtD
Metoclopramide—Feeling abnormal—Vinorelbine—ovarian cancer	0.00232	0.003	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—ovarian cancer	0.00231	0.00299	CcSEcCtD
Metoclopramide—Asthenia—Melphalan—ovarian cancer	0.00231	0.00299	CcSEcCtD
Metoclopramide—Nervousness—Paclitaxel—ovarian cancer	0.00225	0.00292	CcSEcCtD
Metoclopramide—Diarrhoea—Topotecan—ovarian cancer	0.00225	0.00291	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.00225	0.00291	CcSEcCtD
Metoclopramide—CYP2D6—female reproductive system—ovarian cancer	0.00224	0.0149	CbGeAlD
Metoclopramide—Urticaria—Vinorelbine—ovarian cancer	0.00223	0.00289	CcSEcCtD
Metoclopramide—Muscle spasms—Paclitaxel—ovarian cancer	0.00223	0.00289	CcSEcCtD
Metoclopramide—Body temperature increased—Vinorelbine—ovarian cancer	0.00222	0.00288	CcSEcCtD
Metoclopramide—Diarrhoea—Melphalan—ovarian cancer	0.0022	0.00285	CcSEcCtD
Metoclopramide—Nausea—Chlorambucil—ovarian cancer	0.00219	0.00284	CcSEcCtD
Metoclopramide—Visual impairment—Docetaxel—ovarian cancer	0.00218	0.00282	CcSEcCtD
Metoclopramide—Dizziness—Topotecan—ovarian cancer	0.00217	0.00282	CcSEcCtD
Metoclopramide—Tremor—Paclitaxel—ovarian cancer	0.00217	0.00281	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—ovarian cancer	0.00214	0.00277	CcSEcCtD
Metoclopramide—Agitation—Paclitaxel—ovarian cancer	0.00213	0.00276	CcSEcCtD
Metoclopramide—Angioedema—Paclitaxel—ovarian cancer	0.00212	0.00274	CcSEcCtD
Metoclopramide—Flushing—Docetaxel—ovarian cancer	0.0021	0.00271	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—ovarian cancer	0.00209	0.00271	CcSEcCtD
Metoclopramide—Leukopenia—Paclitaxel—ovarian cancer	0.00208	0.00269	CcSEcCtD
Metoclopramide—Rash—Topotecan—ovarian cancer	0.00207	0.00268	CcSEcCtD
Metoclopramide—Hypersensitivity—Vinorelbine—ovarian cancer	0.00207	0.00268	CcSEcCtD
Metoclopramide—Dermatitis—Topotecan—ovarian cancer	0.00207	0.00268	CcSEcCtD
Metoclopramide—Headache—Topotecan—ovarian cancer	0.00206	0.00267	CcSEcCtD
Metoclopramide—Palpitations—Paclitaxel—ovarian cancer	0.00205	0.00265	CcSEcCtD
Metoclopramide—CYP2D6—female gonad—ovarian cancer	0.00204	0.0136	CbGeAlD
Metoclopramide—Rash—Melphalan—ovarian cancer	0.00203	0.00263	CcSEcCtD
Metoclopramide—Dermatitis—Melphalan—ovarian cancer	0.00203	0.00263	CcSEcCtD
Metoclopramide—Asthenia—Vinorelbine—ovarian cancer	0.00202	0.00261	CcSEcCtD
Metoclopramide—Convulsion—Paclitaxel—ovarian cancer	0.00201	0.0026	CcSEcCtD
Metoclopramide—Hypertension—Paclitaxel—ovarian cancer	0.002	0.00259	CcSEcCtD
Metoclopramide—Anxiety—Paclitaxel—ovarian cancer	0.00197	0.00255	CcSEcCtD
Metoclopramide—Nausea—Topotecan—ovarian cancer	0.00195	0.00253	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—ovarian cancer	0.00194	0.00251	CcSEcCtD
Metoclopramide—Diarrhoea—Vinorelbine—ovarian cancer	0.00192	0.00249	CcSEcCtD
Metoclopramide—Nausea—Melphalan—ovarian cancer	0.00191	0.00248	CcSEcCtD
Metoclopramide—Confusional state—Paclitaxel—ovarian cancer	0.00191	0.00247	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—ovarian cancer	0.0019	0.00246	CcSEcCtD
Metoclopramide—Oedema—Paclitaxel—ovarian cancer	0.00189	0.00245	CcSEcCtD
Metoclopramide—Muscle spasms—Docetaxel—ovarian cancer	0.00189	0.00245	CcSEcCtD
Metoclopramide—Dizziness—Vinorelbine—ovarian cancer	0.00186	0.00241	CcSEcCtD
Metoclopramide—Tachycardia—Paclitaxel—ovarian cancer	0.00185	0.00239	CcSEcCtD
Metoclopramide—CYP2D6—testis—ovarian cancer	0.00181	0.012	CbGeAlD
Metoclopramide—Sunitinib—ABCB1—ovarian cancer	0.00178	0.108	CrCbGaD
Metoclopramide—Neutropenia—Epirubicin—ovarian cancer	0.00178	0.0023	CcSEcCtD
Metoclopramide—Rash—Vinorelbine—ovarian cancer	0.00177	0.0023	CcSEcCtD
Metoclopramide—Dermatitis—Vinorelbine—ovarian cancer	0.00177	0.00229	CcSEcCtD
Metoclopramide—Hypotension—Paclitaxel—ovarian cancer	0.00177	0.00229	CcSEcCtD
Metoclopramide—Headache—Vinorelbine—ovarian cancer	0.00176	0.00228	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—ovarian cancer	0.00176	0.00228	CcSEcCtD
Metoclopramide—Leukopenia—Docetaxel—ovarian cancer	0.00176	0.00228	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—ovarian cancer	0.00176	0.00228	CcSEcCtD
Metoclopramide—Palpitations—Docetaxel—ovarian cancer	0.00174	0.00225	CcSEcCtD
Metoclopramide—Insomnia—Paclitaxel—ovarian cancer	0.00171	0.00222	CcSEcCtD
Metoclopramide—Convulsion—Docetaxel—ovarian cancer	0.0017	0.0022	CcSEcCtD
Metoclopramide—Hypertension—Docetaxel—ovarian cancer	0.0017	0.0022	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—ovarian cancer	0.0017	0.0022	CcSEcCtD
Metoclopramide—Dyspnoea—Paclitaxel—ovarian cancer	0.00169	0.00218	CcSEcCtD
Metoclopramide—Somnolence—Paclitaxel—ovarian cancer	0.00168	0.00218	CcSEcCtD
Metoclopramide—Nausea—Vinorelbine—ovarian cancer	0.00167	0.00216	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—ovarian cancer	0.00165	0.00214	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—ovarian cancer	0.00165	0.00213	CcSEcCtD
Metoclopramide—Fatigue—Paclitaxel—ovarian cancer	0.00163	0.00211	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—ovarian cancer	0.00163	0.00211	CcSEcCtD
Metoclopramide—Confusional state—Docetaxel—ovarian cancer	0.00162	0.00209	CcSEcCtD
Metoclopramide—Oedema—Docetaxel—ovarian cancer	0.0016	0.00208	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—ovarian cancer	0.00158	0.00205	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—ovarian cancer	0.00157	0.00203	CcSEcCtD
Metoclopramide—Tachycardia—Docetaxel—ovarian cancer	0.00157	0.00203	CcSEcCtD
Metoclopramide—Feeling abnormal—Paclitaxel—ovarian cancer	0.00156	0.00202	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—ovarian cancer	0.00155	0.00201	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—ovarian cancer	0.00153	0.00198	CcSEcCtD
Metoclopramide—Urticaria—Paclitaxel—ovarian cancer	0.0015	0.00195	CcSEcCtD
Metoclopramide—Hypotension—Docetaxel—ovarian cancer	0.0015	0.00194	CcSEcCtD
Metoclopramide—Body temperature increased—Paclitaxel—ovarian cancer	0.0015	0.00194	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—ovarian cancer	0.00147	0.0019	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—ovarian cancer	0.00146	0.0019	CcSEcCtD
Metoclopramide—Insomnia—Docetaxel—ovarian cancer	0.00145	0.00188	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—ovarian cancer	0.00143	0.00186	CcSEcCtD
Metoclopramide—Dyspnoea—Docetaxel—ovarian cancer	0.00143	0.00185	CcSEcCtD
Metoclopramide—Somnolence—Docetaxel—ovarian cancer	0.00143	0.00185	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—ovarian cancer	0.00141	0.00183	CcSEcCtD
Metoclopramide—Hypersensitivity—Paclitaxel—ovarian cancer	0.00139	0.00181	CcSEcCtD
Metoclopramide—Fatigue—Docetaxel—ovarian cancer	0.00138	0.00179	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—ovarian cancer	0.00136	0.00176	CcSEcCtD
Metoclopramide—Asthenia—Paclitaxel—ovarian cancer	0.00136	0.00176	CcSEcCtD
Metoclopramide—Feeling abnormal—Docetaxel—ovarian cancer	0.00132	0.00171	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—ovarian cancer	0.00131	0.00169	CcSEcCtD
Metoclopramide—Diarrhoea—Paclitaxel—ovarian cancer	0.00129	0.00168	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—ovarian cancer	0.00129	0.00167	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—ovarian cancer	0.00127	0.00165	CcSEcCtD
Metoclopramide—Body temperature increased—Docetaxel—ovarian cancer	0.00127	0.00164	CcSEcCtD
Metoclopramide—Dizziness—Paclitaxel—ovarian cancer	0.00125	0.00162	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—ovarian cancer	0.00122	0.00158	CcSEcCtD
Metoclopramide—Rash—Paclitaxel—ovarian cancer	0.00119	0.00154	CcSEcCtD
Metoclopramide—Dermatitis—Paclitaxel—ovarian cancer	0.00119	0.00154	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—ovarian cancer	0.00119	0.00154	CcSEcCtD
Metoclopramide—Leukopenia—Epirubicin—ovarian cancer	0.00119	0.00154	CcSEcCtD
Metoclopramide—Headache—Paclitaxel—ovarian cancer	0.00119	0.00153	CcSEcCtD
Metoclopramide—Hypersensitivity—Docetaxel—ovarian cancer	0.00118	0.00153	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—ovarian cancer	0.00118	0.00153	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—ovarian cancer	0.00117	0.00152	CcSEcCtD
Metoclopramide—Asthenia—Docetaxel—ovarian cancer	0.00115	0.00149	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—ovarian cancer	0.00115	0.00149	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—ovarian cancer	0.00114	0.00148	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—ovarian cancer	0.00113	0.00146	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—ovarian cancer	0.00112	0.00146	CcSEcCtD
Metoclopramide—Nausea—Paclitaxel—ovarian cancer	0.00112	0.00146	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—ovarian cancer	0.0011	0.00142	CcSEcCtD
Metoclopramide—Diarrhoea—Docetaxel—ovarian cancer	0.0011	0.00142	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—ovarian cancer	0.00109	0.00141	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—ovarian cancer	0.00108	0.0014	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—ovarian cancer	0.00108	0.0014	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—ovarian cancer	0.00106	0.00138	CcSEcCtD
Metoclopramide—Dizziness—Docetaxel—ovarian cancer	0.00106	0.00137	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—ovarian cancer	0.00106	0.00137	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—ovarian cancer	0.00106	0.00137	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—ovarian cancer	0.00104	0.00135	CcSEcCtD
Metoclopramide—Rash—Docetaxel—ovarian cancer	0.00101	0.00131	CcSEcCtD
Metoclopramide—Hypotension—Epirubicin—ovarian cancer	0.00101	0.00131	CcSEcCtD
Metoclopramide—Dermatitis—Docetaxel—ovarian cancer	0.00101	0.00131	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—ovarian cancer	0.00101	0.00131	CcSEcCtD
Metoclopramide—Headache—Docetaxel—ovarian cancer	0.001	0.0013	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—ovarian cancer	0.001	0.0013	CcSEcCtD
Metoclopramide—Insomnia—Epirubicin—ovarian cancer	0.000978	0.00127	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—ovarian cancer	0.000977	0.00126	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—ovarian cancer	0.000964	0.00125	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—ovarian cancer	0.000962	0.00125	CcSEcCtD
Metoclopramide—Nausea—Docetaxel—ovarian cancer	0.000953	0.00123	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—ovarian cancer	0.000935	0.00121	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—ovarian cancer	0.000933	0.00121	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—ovarian cancer	0.000905	0.00117	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—ovarian cancer	0.000892	0.00116	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—ovarian cancer	0.000891	0.00115	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—ovarian cancer	0.00089	0.00115	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—ovarian cancer	0.000863	0.00112	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—ovarian cancer	0.000859	0.00111	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—ovarian cancer	0.000855	0.00111	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—ovarian cancer	0.000825	0.00107	CcSEcCtD
Metoclopramide—Hypersensitivity—Epirubicin—ovarian cancer	0.000797	0.00103	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—ovarian cancer	0.000795	0.00103	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—ovarian cancer	0.000791	0.00102	CcSEcCtD
Metoclopramide—Asthenia—Epirubicin—ovarian cancer	0.000776	0.001	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—ovarian cancer	0.00074	0.000958	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—ovarian cancer	0.000737	0.000955	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—ovarian cancer	0.000718	0.00093	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—ovarian cancer	0.000715	0.000926	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—ovarian cancer	0.000685	0.000887	CcSEcCtD
Metoclopramide—Rash—Epirubicin—ovarian cancer	0.000682	0.000883	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—ovarian cancer	0.000681	0.000882	CcSEcCtD
Metoclopramide—Headache—Epirubicin—ovarian cancer	0.000678	0.000877	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—ovarian cancer	0.000662	0.000857	CcSEcCtD
Metoclopramide—Nausea—Epirubicin—ovarian cancer	0.000643	0.000832	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—ovarian cancer	0.000631	0.000817	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—ovarian cancer	0.000631	0.000816	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—ovarian cancer	0.000627	0.000812	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—ovarian cancer	0.000595	0.00077	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—PIK3CG—ovarian cancer	4.63e-05	0.000759	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MTOR—ovarian cancer	4.61e-05	0.000755	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PIK3CB—ovarian cancer	4.61e-05	0.000755	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—ovarian cancer	4.59e-05	0.000751	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.55e-05	0.000745	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYTB—ovarian cancer	4.54e-05	0.000743	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	4.49e-05	0.000736	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CXCL8—ovarian cancer	4.43e-05	0.000725	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HRAS—ovarian cancer	4.4e-05	0.00072	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PGR—ovarian cancer	4.35e-05	0.000712	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CG—ovarian cancer	4.33e-05	0.00071	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CDKN1B—ovarian cancer	4.32e-05	0.000708	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HDAC6—ovarian cancer	4.31e-05	0.000705	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—IL6—ovarian cancer	4.29e-05	0.000703	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AKT1—ovarian cancer	4.28e-05	0.0007	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PPP2R1A—ovarian cancer	4.25e-05	0.000696	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CASP3—ovarian cancer	4.24e-05	0.000694	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL2—ovarian cancer	4.23e-05	0.000693	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HDAC6—ovarian cancer	4.22e-05	0.00069	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL6—ovarian cancer	4.21e-05	0.00069	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—IL6—ovarian cancer	4.2e-05	0.000688	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PPP2R1A—ovarian cancer	4.16e-05	0.000681	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	4.16e-05	0.000681	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCND1—ovarian cancer	4.12e-05	0.000676	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CB—ovarian cancer	4.12e-05	0.000675	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CG—ovarian cancer	4.09e-05	0.00067	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CTNNB1—ovarian cancer	4.08e-05	0.000669	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL8—ovarian cancer	4.08e-05	0.000668	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CD—ovarian cancer	4.07e-05	0.000667	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PARP1—ovarian cancer	4.04e-05	0.000662	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MMP9—ovarian cancer	4e-05	0.000656	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL8—ovarian cancer	3.99e-05	0.000654	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTEN—ovarian cancer	3.98e-05	0.000652	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	3.98e-05	0.000652	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPP1CC—ovarian cancer	3.96e-05	0.000649	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—BRIP1—ovarian cancer	3.96e-05	0.000649	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AKT1—ovarian cancer	3.88e-05	0.000636	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6ST—ovarian cancer	3.87e-05	0.000634	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—YAP1—ovarian cancer	3.81e-05	0.000624	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CD—ovarian cancer	3.81e-05	0.000624	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—XIAP—ovarian cancer	3.73e-05	0.000612	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—YAP1—ovarian cancer	3.73e-05	0.000611	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CG—ovarian cancer	3.72e-05	0.000609	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—XIAP—ovarian cancer	3.65e-05	0.000599	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SMARCA4—ovarian cancer	3.64e-05	0.000596	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CD—ovarian cancer	3.6e-05	0.000589	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—ovarian cancer	3.6e-05	0.000589	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SMARCA4—ovarian cancer	3.56e-05	0.000583	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STAT3—ovarian cancer	3.56e-05	0.000583	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTEN—ovarian cancer	3.56e-05	0.000583	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EREG—ovarian cancer	3.55e-05	0.000582	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NRAS—ovarian cancer	3.55e-05	0.000582	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CB—ovarian cancer	3.55e-05	0.000582	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EREG—ovarian cancer	3.48e-05	0.000569	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK3—ovarian cancer	3.4e-05	0.000557	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PGR—ovarian cancer	3.33e-05	0.000545	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CB—ovarian cancer	3.32e-05	0.000544	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MYC—ovarian cancer	3.31e-05	0.000542	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PPP2R1A—ovarian cancer	3.28e-05	0.000537	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CD—ovarian cancer	3.27e-05	0.000535	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PGR—ovarian cancer	3.26e-05	0.000534	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK1—ovarian cancer	3.24e-05	0.00053	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EGFR—ovarian cancer	3.24e-05	0.00053	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CB—ovarian cancer	3.14e-05	0.000514	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CG—ovarian cancer	3.13e-05	0.000513	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PARP1—ovarian cancer	3.09e-05	0.000507	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTEN—ovarian cancer	3.07e-05	0.000502	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CG—ovarian cancer	3.06e-05	0.000502	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KRAS—ovarian cancer	3.06e-05	0.000501	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PARP1—ovarian cancer	3.03e-05	0.000496	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL8—ovarian cancer	3.01e-05	0.000494	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6ST—ovarian cancer	2.96e-05	0.000485	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6ST—ovarian cancer	2.9e-05	0.000474	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—IL2—ovarian cancer	2.88e-05	0.000472	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTEN—ovarian cancer	2.87e-05	0.00047	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CB—ovarian cancer	2.85e-05	0.000466	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CG—ovarian cancer	2.84e-05	0.000466	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PIK3CA—ovarian cancer	2.81e-05	0.00046	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CG—ovarian cancer	2.78e-05	0.000456	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CD—ovarian cancer	2.75e-05	0.000451	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL8—ovarian cancer	2.74e-05	0.000448	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—ovarian cancer	2.72e-05	0.000445	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CD—ovarian cancer	2.69e-05	0.000441	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—YAP1—ovarian cancer	2.66e-05	0.000436	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2—ovarian cancer	2.62e-05	0.000428	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TERT—ovarian cancer	2.61e-05	0.000427	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—ovarian cancer	2.6e-05	0.000426	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CA—ovarian cancer	2.51e-05	0.000411	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PPP2R1A—ovarian cancer	2.51e-05	0.000411	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CD—ovarian cancer	2.5e-05	0.00041	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—ovarian cancer	2.49e-05	0.000407	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PPP2R1A—ovarian cancer	2.46e-05	0.000402	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CD—ovarian cancer	2.45e-05	0.000401	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CAV1—ovarian cancer	2.41e-05	0.000395	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CB—ovarian cancer	2.4e-05	0.000393	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CB—ovarian cancer	2.35e-05	0.000385	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ESR1—ovarian cancer	2.32e-05	0.00038	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—ovarian cancer	2.31e-05	0.000378	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—ovarian cancer	2.29e-05	0.000376	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6ST—ovarian cancer	2.28e-05	0.000374	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—ovarian cancer	2.26e-05	0.00037	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—ovarian cancer	2.2e-05	0.000361	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APC—ovarian cancer	2.2e-05	0.00036	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CG—ovarian cancer	2.2e-05	0.00036	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—NRAS—ovarian cancer	2.2e-05	0.00036	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CB—ovarian cancer	2.18e-05	0.000357	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—FASN—ovarian cancer	2.17e-05	0.000355	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—ovarian cancer	2.16e-05	0.000354	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—ovarian cancer	2.16e-05	0.000353	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CB—ovarian cancer	2.13e-05	0.000349	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.13e-05	0.000349	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK3—ovarian cancer	2.1e-05	0.000344	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—ovarian cancer	2.09e-05	0.000343	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.06e-05	0.000337	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—ovarian cancer	2.05e-05	0.000336	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—ovarian cancer	2.05e-05	0.000336	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—ovarian cancer	2.02e-05	0.000332	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—ovarian cancer	2e-05	0.000328	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK1—ovarian cancer	2e-05	0.000328	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—ovarian cancer	2e-05	0.000328	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TERT—ovarian cancer	1.99e-05	0.000327	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.97e-05	0.000323	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—ovarian cancer	1.96e-05	0.000321	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TERT—ovarian cancer	1.95e-05	0.00032	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CD—ovarian cancer	1.93e-05	0.000316	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—ovarian cancer	1.91e-05	0.000313	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—ovarian cancer	1.89e-05	0.00031	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CAV1—ovarian cancer	1.84e-05	0.000302	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CAV1—ovarian cancer	1.8e-05	0.000296	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ESR1—ovarian cancer	1.78e-05	0.000291	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—ovarian cancer	1.77e-05	0.00029	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.75e-05	0.000287	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6ST—ovarian cancer	1.75e-05	0.000286	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ESR1—ovarian cancer	1.74e-05	0.000285	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—ovarian cancer	1.74e-05	0.000284	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6ST—ovarian cancer	1.71e-05	0.00028	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—ovarian cancer	1.7e-05	0.000279	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MTOR—ovarian cancer	1.68e-05	0.000276	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CB—ovarian cancer	1.68e-05	0.000276	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CG—ovarian cancer	1.68e-05	0.000275	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APC—ovarian cancer	1.68e-05	0.000275	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—NRAS—ovarian cancer	1.68e-05	0.000275	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—ovarian cancer	1.65e-05	0.000271	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CG—ovarian cancer	1.64e-05	0.000269	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APC—ovarian cancer	1.64e-05	0.000269	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—NRAS—ovarian cancer	1.64e-05	0.000269	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.63e-05	0.000266	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—ovarian cancer	1.62e-05	0.000265	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK3—ovarian cancer	1.61e-05	0.000264	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—ovarian cancer	1.61e-05	0.000263	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMS—ovarian cancer	1.6e-05	0.000262	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1B—ovarian cancer	1.58e-05	0.000259	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK3—ovarian cancer	1.57e-05	0.000258	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—ovarian cancer	1.56e-05	0.000256	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP3—ovarian cancer	1.55e-05	0.000253	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—ovarian cancer	1.54e-05	0.000253	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—ovarian cancer	1.54e-05	0.000252	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK1—ovarian cancer	1.53e-05	0.000251	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—ovarian cancer	1.53e-05	0.000251	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—ovarian cancer	1.51e-05	0.000247	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK1—ovarian cancer	1.5e-05	0.000245	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—ovarian cancer	1.5e-05	0.000245	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CTNNB1—ovarian cancer	1.49e-05	0.000244	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CD—ovarian cancer	1.48e-05	0.000242	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—ovarian cancer	1.46e-05	0.00024	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—ovarian cancer	1.46e-05	0.00024	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—ovarian cancer	1.45e-05	0.000238	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—ovarian cancer	1.45e-05	0.000237	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CD—ovarian cancer	1.45e-05	0.000237	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	1.43e-05	0.000235	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—ovarian cancer	1.42e-05	0.000232	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—ovarian cancer	1.42e-05	0.000232	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—ovarian cancer	1.33e-05	0.000218	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—ovarian cancer	1.31e-05	0.000215	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—ovarian cancer	1.3e-05	0.000214	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—ovarian cancer	1.3e-05	0.000213	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—ovarian cancer	1.3e-05	0.000213	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NRAS—ovarian cancer	1.3e-05	0.000212	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MTOR—ovarian cancer	1.29e-05	0.000211	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	1.29e-05	0.000211	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CAV1—ovarian cancer	1.29e-05	0.000211	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—ovarian cancer	1.28e-05	0.000209	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CB—ovarian cancer	1.26e-05	0.000206	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MTOR—ovarian cancer	1.26e-05	0.000206	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK3—ovarian cancer	1.24e-05	0.000203	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—ovarian cancer	1.24e-05	0.000203	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—ovarian cancer	1.23e-05	0.000201	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—ovarian cancer	1.21e-05	0.000198	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—ovarian cancer	1.21e-05	0.000198	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	1.21e-05	0.000198	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—ovarian cancer	1.2e-05	0.000197	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	1.19e-05	0.000196	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP3—ovarian cancer	1.18e-05	0.000194	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1B—ovarian cancer	1.18e-05	0.000194	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—ovarian cancer	1.18e-05	0.000194	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK1—ovarian cancer	1.18e-05	0.000194	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—ovarian cancer	1.18e-05	0.000194	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—ovarian cancer	1.18e-05	0.000193	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.17e-05	0.000192	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—ovarian cancer	1.17e-05	0.000192	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP3—ovarian cancer	1.16e-05	0.00019	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—ovarian cancer	1.16e-05	0.00019	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—ovarian cancer	1.15e-05	0.000189	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—ovarian cancer	1.15e-05	0.000189	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	1.14e-05	0.000187	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—ovarian cancer	1.13e-05	0.000185	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.12e-05	0.000183	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	1.12e-05	0.000183	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—ovarian cancer	1.12e-05	0.000183	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.11e-05	0.000182	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—ovarian cancer	1.1e-05	0.000179	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—ovarian cancer	1.09e-05	0.000178	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.09e-05	0.000178	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	1.06e-05	0.000174	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.03e-05	0.000169	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	1.03e-05	0.000168	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1e-05	0.000165	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—ovarian cancer	9.95e-06	0.000163	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRAS—ovarian cancer	9.92e-06	0.000163	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—ovarian cancer	9.92e-06	0.000163	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	9.83e-06	0.000161	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—ovarian cancer	9.74e-06	0.000159	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRAS—ovarian cancer	9.71e-06	0.000159	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK3—ovarian cancer	9.5e-06	0.000156	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—ovarian cancer	9.49e-06	0.000155	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	9.3e-06	0.000152	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—ovarian cancer	9.24e-06	0.000151	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—ovarian cancer	9.08e-06	0.000149	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—ovarian cancer	9.05e-06	0.000148	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK1—ovarian cancer	9.04e-06	0.000148	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—ovarian cancer	9.04e-06	0.000148	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CB—ovarian cancer	8.98e-06	0.000147	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	8.85e-06	0.000145	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—ovarian cancer	8.85e-06	0.000145	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—ovarian cancer	8.54e-06	0.00014	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—ovarian cancer	8.38e-06	0.000137	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—ovarian cancer	8.36e-06	0.000137	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	7.85e-06	0.000129	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—ovarian cancer	7.76e-06	0.000127	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	7.68e-06	0.000126	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—ovarian cancer	7.59e-06	0.000124	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—ovarian cancer	7.43e-06	0.000122	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—ovarian cancer	7.26e-06	0.000119	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—ovarian cancer	7.11e-06	0.000116	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—ovarian cancer	6.95e-06	0.000114	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—ovarian cancer	6.8e-06	0.000111	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—ovarian cancer	6.41e-06	0.000105	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—ovarian cancer	6.27e-06	0.000103	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—ovarian cancer	5.47e-06	8.97e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—ovarian cancer	4.47e-06	7.33e-05	CbGpPWpGaD
